Suspension of trading

Analyst Reco. Avidity Biosciences, Inc.

Equities

RNA

US05370A1088

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-26 pm EST			5-day change	1st Jan Change
72.82 ^USD	+0.03%		-.--%	+0.96%

Mar. 17	Novartis Raises $11 Billion to Fund Avidity Biosciences Deal	MT
Mar. 16	Novartis Unit Files to Sell Notes to Repay Loan for Avidity Biosciences Acquisition	MT

Analyst Reco.

Dec. 18	Evercore ISI Downgrades Avidity Biosciences to In Line From Outperform, Adjusts Price Target to $72 From $65	MT
Dec. 10	Dyne Therapeutics' Biggest Catalyst is Avidity Biosciences' DM1 Readout in H2 2026, Oppenheimer Says	MT
Nov. 07	Chardan Downgrades Avidity Biosciences to Neutral From Buy	MT
25-10-29	Wolfe Research Downgrades Avidity Biosciences to Peer Perform From Outperform	MT
25-10-29	TD Cowen Downgrades Avidity Biosciences to Hold From Buy, Adjusts Price Target to $74 From $78	MT
25-10-28	Chardan Downgrades Avidity Biosciences to Neutral From Buy, Trims Price Target to $72 From $75	MT
25-10-28	RBC Downgrades Avidity Biosciences to Sector Perform From Outperform, Raises Price Target to $72 From $61, Keeps Speculative Risk	MT
25-10-27	Dyne Therapeutics Shares Rise After Novartis Reaches Deal to Buy Avidity	DJ
25-10-27	Needham Downgrades Avidity Biosciences to Hold From Buy	MT
25-10-27	Bernstein Downgrades Avidity Biosciences to Market Perform From Outperform, Adjusts PT to $72 From $52	MT
25-10-27	Raymond James Downgrades Avidity Biosciences to Market Perform From Strong Buy	MT
25-10-27	HC Wainwright Downgrades Avidity Biosciences to Neutral From Buy, $87 Price Target	MT
25-10-27	Swiss stocks - Factors to watch on October 27	RE
25-10-26	Certain Pre-funded warrants of Avidity Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 27-OCT-2025.	CI
25-10-26	Certain Options of Avidity Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 27-OCT-2025.	CI
25-10-26	Novartis said to near $70-per-share-plus deal for Avidity - Bloomberg News	RE
25-10-13	Avidity Biosciences, Inc. Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for First Quarter of 2026	CI
25-10-13	Avidity Biosciences Completes FDA Pre-BLA Meeting for Del-Zota, Targets 2026 Submission	MT
25-10-13	Avidity Biosciences announces positive pre-BLA meeting with US FDA for del-zota in DMD44	RE
25-09-17	Roth Capital Partners Initiates Avidity Biosciences at Buy	MT
25-09-12	HC Wainwright Adjusts Avidity Biosciences Price Target to $87 From $68, Maintains Buy Rating	MT
25-06-24	Bernstein Initiates Avidity Biosciences at Outperform With $50 Price Target	MT
25-06-17	Wolfe Research Initiates Coverage on Avidity Biosciences With Outperform Rating, $55 Price Target	MT
25-03-13	Citigroup Initiates Avidity Biosciences Inc at Buy With $70 Price Target	MT
25-03-12	BMO Capital Initiates Avidity Biosciences at Outperform With $72 Price Target	MT